$72 Million - Initial Public OfferingJoint Bookrunner
BridgeBio Pharma, Inc.
$401 Million - Initial Public OfferingJoint Bookrunner
$104 Million - Follow-OnJoint Bookrunner
ABBV / Upgrading the New Cash King – More Diversified, More Durable, Cheaper, OP, $88 / Outperform
Biopharma / American Psychiatric Association (APA) 2019: Core Takeaways and Industry Themes
Medical Devices-Cardiology/U.S. TAVR Survey: 1Q19 Again Light vs. Street, Points to In-Line Sales, at Best